Iovance Biotherapeutics Inc Stock News

Experienced investors understand that being in the stock market requires a long-term, multiyear mindset. For truly patient people though, the reward is well worth the wait; you'd be hard-pressed to find better returns on your money than the market's average annual gain of about 10%.

Investors are typically quite harsh on publicly traded companies that don't make their quarterly estimates, a dynamic vividly on display Friday with biotech stock Iovance Biotherapeutics (IOVA -20.08%). The company published its second-quarter earnings after market close the previous day, and the market reacted by trading the stock down by more than 20%.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Daniel G. Kirby - Chief Commercial Officer Frederick G.

Iovance (IOVA) Q2 Revenue Jumps 93%

$60.0M in 2Q25 Total Product Revenue More than 100 Patients Treated with Amtagvi® in 2Q25 Strategic Restructuring Extends Cash Runway into 4Q26 FY25 Total Product Revenue Guidance of $250M-$300M Reiterated SAN CARLOS, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel ...

Shares of Iovance Biotherapeutics (IOVA -1.02%) have been in a free fall this past year, but in recent weeks, they have experienced a bit of a surge in value. The volatile biotech stock has been picking up steam, and the share price is up roughly 67% in just the past month.

Shares of Iovance Biotherapeutics (IOVA -5.91%) are down about 75% from a high-water mark they set last December. Up and down Wall Street, investment bank analysts tasked with following the commercial-stage cancer drug developer are arguing about whether it's fallen too far or not far enough.

Iova stock rallied 32% on Wednesday, snapping out of a long, sluggish stretch that had frustrated investors for months. The Iovance Biotherapeutics (NASDAQ: IOVA) shares have been stuck in a tight range after a rough year, but today's move was sharp enough to turn heads.